QUIA Stock Overview
QuiaPEG Pharmaceuticals Holding AB (publ) engages in the research, development, and commercialization of medicines based on Uni-Qleaver, a drug delivery platform.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
QuiaPEG Pharmaceuticals Holding AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.075 |
| 52 Week High | kr2.40 |
| 52 Week Low | kr0.026 |
| Beta | 0.92 |
| 1 Month Change | 29.83% |
| 3 Month Change | -2.08% |
| 1 Year Change | -94.84% |
| 3 Year Change | -99.93% |
| 5 Year Change | n/a |
| Change since IPO | -99.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| QUIA | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -6.0% | -0.06% | 0.9% |
| 1Y | -94.8% | -5.3% | 10.3% |
Return vs Industry: QUIA underperformed the Swedish Biotechs industry which returned -4.3% over the past year.
Return vs Market: QUIA underperformed the Swedish Market which returned 10.7% over the past year.
Price Volatility
| QUIA volatility | |
|---|---|
| QUIA Average Weekly Movement | 19.5% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 13.0% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: QUIA's share price has been volatile over the past 3 months.
Volatility Over Time: QUIA's weekly volatility has decreased from 28% to 19% over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 3 | Marcus Bosson | www.quiapeg.com |
QuiaPEG Pharmaceuticals Holding AB (publ) engages in the research, development, and commercialization of medicines based on Uni-Qleaver, a drug delivery platform. The company develops drugs through its pegylation technology platform. Its product pipeline includes QPG-1030 (pegylated teduglutide) for the treatment of short bowel syndrome, and QPG-1029 under pre-clinical development for stable plasma concentration, as well as antibody-drug conjugates being developed using the company’s Uni-Qleaver technology-platform.
QuiaPEG Pharmaceuticals Holding AB (publ) Fundamentals Summary
| QUIA fundamental statistics | |
|---|---|
| Market cap | kr5.61m |
| Earnings (TTM) | -kr16.52m |
| Revenue (TTM) | kr4.37m |
1.3x
P/S Ratio-0.3x
P/E RatioIs QUIA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| QUIA income statement (TTM) | |
|---|---|
| Revenue | kr4.37m |
| Cost of Revenue | kr2.20m |
| Gross Profit | kr2.17m |
| Other Expenses | kr18.69m |
| Earnings | -kr16.52m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.22 |
| Gross Margin | 49.63% |
| Net Profit Margin | -377.75% |
| Debt/Equity Ratio | 135.1% |
How did QUIA perform over the long term?
See historical performance and comparison